A 2026 German-Austrian cohort analysis found that people with schizophrenia who were taking quetiapine scored modestly higher on demanding working-memory tests than sex- and age-matched patients who were not, with the largest gap at doses of 300 mg a day or less.1 Because patients were not randomized to quetiapine, this is an association; the advantage …
At entry to US specialty clinics, 34% of 2,951 young people with first-episode psychosis reported suicidal thoughts and 7% had attempted suicide in the previous 6 months. A 2026 Early Psychosis Intervention Network (EPINET) analysis found odds fell 76% for thoughts and 85% for attempts over 2 years of care.1 With no comparison group, the …
A 2026 analysis of 41 randomized studies involving 21,025 adults with schizophrenia found the largest estimated reductions in hostility and aggression for clozapine (standardized mean difference, or SMD, of −0.75), paliperidone (−0.62), and olanzapine (−0.60) vs. placebo.1 Confidence in every comparison was low or very low, the top 3 were not statistically separable, and most …
A 2026 case report described valproate 800 mg/day improving agitation in residual-phase treatment-resistant schizophrenia but being followed by hypoglycemia and pancytopenia; after discontinuation, lithium 600 mg/day at 0.8 mEq/L was associated with BPRS improvement from 80 to 64.1 The calibrated read is mixed: valproate looked behaviorally useful in 1 patient, but the safety signal was …
A 254-person FaceYourFears moderator analysis found that people with schizophrenia-spectrum paranoia and higher avolition or moderate-to-high delusion severity may improve more with virtual-reality CBT than with standard CBT for psychosis.1 The result is useful as a treatment-matching hypothesis, not as a rule that assigns patients to a headset. Research Highlights 254 participants were analyzed: 128 …
A 2026 randomized study involving 80 people with schizophrenia found that adding high-frequency repetitive transcranial magnetic stimulation to risperidone improved PANSS cognitive-factor scores and aggressive-behavior ratings more than risperidone alone over 4 weeks.1 Research Highlights Design was randomized but short: 80 patients were assigned to risperidone alone or risperidone plus rTMS, 40 per group, with …
A 2026 meta-analysis of 8 controlled trials found that AVATAR therapy reduced auditory verbal hallucination severity after treatment, Hedges’ g = −0.40, 95% CI −0.54 to −0.25, across 978 participants.1 The signal is real, but the strongest reading is short-term symptom calibration rather than a finished replacement for standard psychosis care. Research Highlights Voice severity …